SB 671, as amended, Hill. Pharmacy: biological product.
The Pharmacy Law governs the practice of pharmacy in this state, including the permissible duties of licensed pharmacists. The Pharmacy Law authorizes a pharmacist filling a prescription order for a drug product prescribed by its trade or brand name to select another drug product with the same active chemical ingredients of the same strength, quantity, and dosage form, and of the same generic drug name as determined, as specified, of those drug products having the same active chemical ingredients. A knowing violation of the Pharmacy Law is a misdemeanor.
This bill, except as specified, would authorize a pharmacist to select an alternative biological product when filling a prescription order for a prescribed biological product if the alternative biological product is interchangeable, as defined, and the prescriber does not personally indicate in a prescribed manner that a substitution is not to be made. The bill would require a pharmacist or a designee, within a specified period following the dispensing of a biological product, to make an electronically accessible entry in a described entry system of the specific biological product provided to the patient. The bill would provide an alternate means of communicating the name of the biological product dispensed to the prescriber if the pharmacy does not have access to one or more of the described entry systems. The bill would also require that the substitution of a biological product be communicated to the patient. The bill would prohibit a pharmacist from selecting an alternative biological product that meets the requirements of these provisions unless the cost to the patient of the alternative biological product selected is the same or less than the cost of the prescribed biological product. Because a knowing violation of these requirements would be a misdemeanor, the bill would create new crimes, thereby imposing a state-mandated local program.
The bill would also require the California State Board of Pharmacy to maintain on its public Internet Web site a link to the current list, if available, of biological products determined by the federal Food and Drug Administration to be interchangeable.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Vote: majority. Appropriation: no. Fiscal committee: yes. State-mandated local program: yes.
The people of the State of California do enact as follows:
Section 4073.5 is added to the Business and
2Professions Code, to read:
(a) A pharmacist filling a prescription order for a
4prescribed biological product may select an alternative biological
5product only if all of the following:
6(1) The alternative biological product is interchangeable.
7(2) The prescriber does not personally indicate “Do not
8substitute,” or words of similar meaning, in the manner provided
9in subdivision (d).
10(b) Within five days following the dispensing of a biological
11product, a dispensing pharmacist or the pharmacists’ designee
12shall make an entry of the specific biological product provided to
13the
patient, including the name of the biological product and the
P3 1manufacturer. The communication shall be conveyed by making
2an entry that can be electronically accessed by the prescriber
3begin delete through:end deletebegin insert through one or more of the following electronic records
4systems:end insert
5(1) An interoperable electronic medical records begin deletesystem,end deletebegin insert system.end insert
6(2) An electronic prescribingbegin delete technology,end deletebegin insert
technology.end insert
7(3) A pharmacy benefit managementbegin delete system, orend deletebegin insert system.end insert
8(4) A pharmacy record.
9(c) Entry into an electronic records system as described in
10subdivision (b) is presumed to provide notice to the prescriber.begin delete Ifend delete
11begin insert(d)end insertbegin insert end insertbegin insertIf end insertthe
pharmacy does not have access to one or more of the
12entry systems in subdivision (b), the pharmacist or the pharmacist’s
13designee shall communicate the name of the biological product
14dispensed to the prescriber using facsimile, telephone, electronic
15transmission, or other prevailing means, except that communication
16shall not be required in this instance to the prescriber when either
17of the following apply:
18(1) There is no interchangeable biological product approved by
19the federal Food and Drug Administration for the product
20prescribed.
21(2) A refill prescription is not changed from the product
22dispensed on the prior filling of the prescription.
23(d)
end delete
24begin insert(e)end insert In no case shall a selection be made pursuant to this section
25if the prescriber personally indicates, either orally or in his or her
26own handwriting, “Do not substitute,” or words of similar meaning.
27(1) This subdivision shall not prohibit a prescriber from checking
28a box on a prescription marked “Do not substitute,” provided that
29the prescriber personally initials the box or checkmark.
30(2) To indicate that a selection shall not be made pursuant to
31this section for an electronic data transmission prescription, as
32defined in subdivision (c) of Section 4040, a prescriber may
33indicate “Do not substitute,” or words of similar meaning, in
the
34prescription as transmitted by electronic data, or may check a box
35marked on the prescription “Do not substitute.” In either instance,
36it shall not be required that the prohibition on substitution be
37manually initialed by the prescriber.
38(e)
end delete
39begin insert(f)end insert Selection pursuant to this section is within the discretion of
40the pharmacist, except as provided in subdivisionbegin delete (d).end deletebegin insert
(e).end insert A
P4 1pharmacist who selects an alternative biological product to be
2dispensed pursuant to this section shall assume the same
3responsibility for substituting the biological product as would be
4incurred in filling a prescription for a biological product prescribed
5by name. There shall be no liability on the prescriber for an act or
6omission by a pharmacist in selecting, preparing, or dispensing a
7biological product pursuant to this section. In no case shall the
8pharmacist select a biological product that meets the requirements
9of subdivision (a) unless the cost to the patient of the biological
10product selected is the same or less than the cost of the prescribed
11biological product. Cost, as used in this subdivision, includes any
12professional fee that may be charged by the pharmacist.
13(f)
end delete
14begin insert(g)end insert This section shall apply to all prescriptions, including those
15presented by or on behalf of persons receiving assistance from the
16federal government or pursuant to the Medi-Cal Act set forth in
17Chapter 7 (commencing with Section 14000) of Part 3 of Division
189 of the Welfare and Institutions Code.
19(g)
end delete
20begin insert(h)end insert When a selection is made pursuant to this section, the
21substitution of a biological product shall be communicated to the
22patient.
23(h)
end delete
24begin insert(i)end insert The board shall maintain on its public Internet Web site a
25link to the current list, if available, of biological products
26determined by the federal Food and Drug Administration to be
27interchangeable.
28(i)
end delete
29begin insert(j)end insert For purposes of this section, the following terms shall have
30the following meanings:
31(1) “Biological product” has the same meaning that applies to
32that term under
Section 351 of the federal Public Health Service
33Act (42 U.S.C. Sec. 262(i)).
34(2) “Interchangeable” means a biological product that the federal
35Food and Drug Administration has determined meets the standards
36set forth inbegin delete 42 U.S.C.end delete Sectionbegin delete 262(k)(4),end deletebegin insert
262(k)(4) of Title 42 of
37the United States Code,end insert or has been deemed therapeutically
38equivalent by the federal Food and Drug Administration as set
39forth in the latest addition or supplement of the Approved Drug
40Products with Therapeutic Equivalence Evaluations.
P5 1(3) “Prescription,” with respect to a biological product, means
2a prescription for a product that is subject to Section 503(b) of the
3Federal Food, Drug, and Cosmetic Act (21 U.S.C. Sec. 353(b)).
4(j)
end delete
5begin insert(k)end insert This section shall not prohibit the
administration of
6immunizations, as permitted in Sections 4052 and 4052.8.
7(k)
end delete
8begin insert(l)end insert This section shall not prohibit a disability insurer or health
9care service plan from requiring prior authorization or imposing
10other appropriate utilization controls in approving coverage for
11any biological product.
No reimbursement is required by this act pursuant to
13Section 6 of Article XIII B of the California Constitution because
14the only costs that may be incurred by a local agency or school
15district will be incurred because this act creates a new crime or
16infraction, eliminates a crime or infraction, or changes the penalty
17for a crime or infraction, within the meaning of Section 17556 of
18 the Government Code, or changes the definition of a crime within
19the meaning of Section 6 of Article XIII B of the California
20Constitution.
O
95